In reply: We thank Bowyer and Prentice for their input1 regarding our article2 on this interesting and complex topic.
We agree with the definition of emphysematous pyelonephritis and emphysematous cystitis as described by Bowyer and Prentice. There was indeed gas evident within our patient's left renal collecting system, as shown on a computed tomography scan, which was not included in our published article as we felt that the other published images would be of more interest to readers.
We agree that sodium–glucose cotransporter type 2 (SGLT2) inhibitors cause glycosuria and have been implicated in an increased risk of urinary tract infections.3,4 Our patient had been taking an SGLT2 inhibitor, which was ceased during his first admission.
The occasional association of intestinal strongyloidiasis with gram‐negative sepsis and, in particular, gram‐negative bacillary meningitis, is well recognised. However, strongyloidiasis was not suspected in our patient, and diagnostic tests for this pathogen were not performed.
- 1. Bowyer J, Prentice DA. Hypervirulent Klebsiella pneumoniae causing emphysematous pyelonephritis: a life‐threatening pathogen within Australian communities [Letter]. Med J Aust 2024; 222: https://doi.org/10.5694/mja2.52541
- 2. Ong KGC, Dyer JR, Hayne D. Hypervirulent Klebsiella pneumoniae causing emphysematous pyelonephritis: a life‐threatening pathogen within Australian communities. Med J Aust 2024; 220: 400‐402. https://www.mja.com.au/journal/2024/220/8/hypervirulent‐klebsiella‐pneumoniae‐causing‐emphysematous‐pyelonephritis‐life
- 3. Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta‐analysis. Sci Rep 2017; 7: 2824.
- 4. Li D, Wang T, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: a meta‐analysis of randomized controlled trials. Diabetes Obes Metab 2017; 19: 348‐355.
No relevant disclosures.